Mabpharm (HKSE:02181) Short Percentage of Float

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02181 Mabpharm Ltd HKSE:02181
38 GF Score
Price HK$0.40
GF Value HK$1.96
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Mabpharm Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

HKSE:02181 vs VRTX, REGN, ALNY: Short Percentage of Float Comparison

For the Biotechnology subindustry, Mabpharm's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mabpharm Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mabpharm's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Mabpharm's Short Percentage of Float falls into.


HKSE:02181
38GF Score
Mabpharm Ltd HKSE:02181
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Mabpharm (HKSE:02181) Overvalued in 2026?

Based on GuruFocus' analysis, Mabpharm stock appears to be undervalued. The current stock price of HK$0.40 is trading 79.8% below its estimated GF Value™ of HK$1.96. GuruFocus considers Mabpharm to be Possible Value Trap.

Key valuation signals for HKSE:02181:

  • Short Percentage of Float:
  • GF Value™: HK$1.96 vs. price of HK$0.40 (79.8% below fair value)
  • GF Score™: 38/100 with 7 warning signs

No single metric tells the full story. See the HKSE:02181 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Mabpharm Business Description

Address Lujia Road East, Koutai Road West, Block G79, China Medical City, Taizhou, CHN, 225300
Mabpharm Ltd is a biopharmaceutical company. The company is engaged in the research, development, and production of new drugs and biosimilars for cancers and autoimmune diseases. Its core products include CMAB008 (infliximab), CMAB007 (omalizumab), and CMAB009 (cetuximab). Company operates in Chinese Mainland and Others.
38GF Score

Get the complete analysis for HKSE:02181

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$0.40
Price
HK$1.96
GF Value